Read about rescue therapy in 48 week open-label safety extension study other endpoints
You may be eligible for the EUCRISA Copay Savings Program if you currently use private or commercial health insurance to cover a portion of your medication costs for EUCRISA.
By using the EUCRISA Copay Savings Card, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:
For questions or additional support, call 1-877-548-1739, write to Pfizer Inc., at PO Box 29387, Mission, KS 66201, or visit the EUCRISA website at www.eucrisa.com.
NEW, Updated Indication: EUCRISA (crisaborole) is indicated for topical treatment of mild to moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.
EUCRISA is for topical use only and is not for ophthalmic, oral, or intravaginal use. For more information, please view the full prescribing information here.
EUCRISA is contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation.
Hypersensitivity reactions, including contact urticaria, have occurred in patients treated with EUCRISA and should be suspected in the event of severe pruritus, swelling and erythema at the application site or at a distant site. Discontinue EUCRISA immediately and initiate appropriate therapy if signs and symptoms of hypersensitivity occur.
The most common adverse reaction occurring in ≥1% of subjects in clinical trials was application site pain, such as burning or stinging.
EUCRISA is indicated for topical treatment of mild-to-moderate atopic dermatitis in patients 2 years of age and older.